We plan to issue several type 2 diabetes blog postings in the coming weeks to highlight findings from a recently published report entitled TreatmentTrends: Type 2 Diabetes. This report provides insights into physician perceptions of type 2 diabetes, based on primary market research of 102 U.S. Endocrinologists (ENDOs) and 55 U.S. PCPs.  For this week, here is a key question and summary findings from the report:

  • What is the preference for certain type 2 diabetes drug classes or brands?
    • TreatmentTrends Type 2 Diabetes (US) covers many of the major classes of type 2 diabetes treatment, including biguanides (metformin), long-acting insulin analogues, DDP-IV inhibitors, short-acting insulin analogues, PPAR-gamma agonists, GLP-1 receptor agonists, and SGLT-2 inhibitors, among many others. Currently, a majority of type 2 diabetes patients are using metformin (excluding fixed-dose combinations) and one-third of patients are treated with long-acting insulins such as Sanofi's Lantus or Novo Nordisk's Levemir.


  • Janssen Pharmaceuticals Invokana, a new SGLT-2 inhibitor approved in March 2013, captures a small percentage of type 2 diabetes patient share, with significant increases expected six months from now. Across all physicians in the study, there are expected significant increases in the use of long-acting insulin analogues, DDP-IV inhibitors, short-acting insulin analogues, GLP-1 receptor agonists, and SGLT-2 inhibitors. The report also finds that, within the GLP-1 drug class, Novo Nordisk's Victoza is the patient share leader, followed by Bristol-Myers Squibb/AstraZeneca's Byetta/Bydureon (if these products are considered independently).
  • Please see additional information in the report regarding what is the physician perception of the drug treatment rate for prediabetics and type 2 diabetics. Also, the report contains information on the average length of time on diabetes treatments, as the following diagram depicts:

    DRG becomes Clarivate

    View Now